Vanguard Fiduciary Trust
UNCY icon

Vanguard Fiduciary Trust’s Unicycive Therapeutics UNCY Stock Holding History

Vanguard Fiduciary Trust’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$699K Buy
148,965
+47,891
+47% +$353K ﹤0.01% 3159
2026
Q1 		$665K Buy
+101,074
New +$662K ﹤0.01% 3108

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Vanguard Fiduciary Trust's UNCY Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Unicycive Therapeutics (UNCY) stake by 47% in Q2 2026, buying an estimated $353K and bringing the position to 148,965 shares worth $699K. The position accounts for ﹤0.01% of the portfolio, ranked #3159.

Vanguard Fiduciary Trust first reported a position in UNCY in Q1 2026 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Vanguard Fiduciary Trust held 148,965 shares of Unicycive Therapeutics worth $699K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 47,891 Unicycive Therapeutics shares in Q2 2026, an estimated $353K.
  • Unicycive Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3159 holding.
  • Vanguard Fiduciary Trust first reported a position in Unicycive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.